BACKGROUND: Obstructive sleep apnea (OSA) has been linked to obesity, inflammation, and metabolic syndrome. The gut microbiota, which serves as reservoir for bacterial lipopolysaccharides (LPS), could be altered by OSA and trigger inflammation. LPS-binding protein (LBP) serves as a surrogate marker of underlying low-grade endotoxemia by LPS from the gut. We hypothesized that systemic LBP levels would be higher in obese children and in those with OSA. METHODS: Consecutive snoring and nonsnoring children (mean age 6.8 ± 1.3 y) were included after overnight polysomnography, and fasting levels of lipids, insulin glucose, and high-sensitivity C-reactive protein were obtained. Children were subdivided into four subgroups based on the presence of obesity or OSA. Plasma LBP levels were assayed using ELISA. RESULTS: Of 219 participants, nonobese controls had the lowest levels of LBP, and the presence of obesity without OSA was associated with significant LBP increases. Nonobese children with OSA exhibited increased LBP levels, with obese children with OSA demonstrating the highest LBP levels of all four groups. Furthermore, LBP was independently associated with body mass index and with measures of OSA severity as well as with metabolic dysfunction, particularly insulin resistance as indicated by the homeostasis model assessment of insulin resistance. CONCLUSIONS: Systemic low-level endotoxemia and resultant systemic inflammation is present in children who are either obese or suffer from OSA and is particularly prominent when both conditions are present. We postulate that disrupted sleep and other factors facilitating obesity such as a high-fat diet may disrupt the gut microbiome and lead to increased systemic LPS levels with resultant inflammation, promoting downstream metabolic dysfunction.
BACKGROUND:Obstructive sleep apnea (OSA) has been linked to obesity, inflammation, and metabolic syndrome. The gut microbiota, which serves as reservoir for bacterial lipopolysaccharides (LPS), could be altered by OSA and trigger inflammation. LPS-binding protein (LBP) serves as a surrogate marker of underlying low-grade endotoxemia by LPS from the gut. We hypothesized that systemic LBP levels would be higher in obesechildren and in those with OSA. METHODS: Consecutive snoring and nonsnoring children (mean age 6.8 ± 1.3 y) were included after overnight polysomnography, and fasting levels of lipids, insulin glucose, and high-sensitivity C-reactive protein were obtained. Children were subdivided into four subgroups based on the presence of obesity or OSA. Plasma LBP levels were assayed using ELISA. RESULTS: Of 219 participants, nonobese controls had the lowest levels of LBP, and the presence of obesity without OSA was associated with significant LBP increases. Nonobese children with OSA exhibited increased LBP levels, with obesechildren with OSA demonstrating the highest LBP levels of all four groups. Furthermore, LBP was independently associated with body mass index and with measures of OSA severity as well as with metabolic dysfunction, particularly insulin resistance as indicated by the homeostasis model assessment of insulin resistance. CONCLUSIONS: Systemic low-level endotoxemia and resultant systemic inflammation is present in children who are either obese or suffer from OSA and is particularly prominent when both conditions are present. We postulate that disrupted sleep and other factors facilitating obesity such as a high-fat diet may disrupt the gut microbiome and lead to increased systemic LPS levels with resultant inflammation, promoting downstream metabolic dysfunction.
Authors: Philipp M Lepper; Marcus E Kleber; Tanja B Grammer; Kristina Hoffmann; Simone Dietz; Bernhard R Winkelmann; Bernhard O Boehm; Winfried März Journal: Atherosclerosis Date: 2011-06-13 Impact factor: 5.162
Authors: G L Su; P D Freeswick; D A Geller; Q Wang; R A Shapiro; Y H Wan; T R Billiar; D J Tweardy; R L Simmons; S C Wang Journal: J Immunol Date: 1994-07-15 Impact factor: 5.422
Authors: Javier Traba; Miriam Kwarteng-Siaw; Tracy C Okoli; Jessica Li; Rebecca D Huffstutler; Amanda Bray; Myron A Waclawiw; Kim Han; Martin Pelletier; Anthony A Sauve; Richard M Siegel; Michael N Sack Journal: J Clin Invest Date: 2015-11-03 Impact factor: 14.808
Authors: Isabel Moreno-Indias; Marta Torres; Lidia Sanchez-Alcoholado; Fernando Cardona; Isaac Almendros; David Gozal; Josep M Montserrat; Maria I Queipo-Ortuño; Ramon Farré Journal: Sleep Date: 2016-10-01 Impact factor: 5.849
Authors: Graziela De Luca Canto; Camila Pachêco-Pereira; Secil Aydinoz; Paul W Major; Carlos Flores-Mir; David Gozal Journal: Sleep Med Rev Date: 2014-11-28 Impact factor: 11.609